{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T23:43:14Z","timestamp":1787010194806,"version":"build-2736575974"},"reference-count":15,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2023,4]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>\n                      Persisting residual masses at treatment completion are known in rhabdomyosarcoma (RMS) treated with definitive radiotherapy (RT) to the primary site, but their prognostic significance is uncertain. Tumor response as assessed by anatomic imaging is not prognostic and studies based on\n                      <jats:sup>18<\/jats:sup>\n                      F-FDG-PET response are limited. We report the prognostic significance of persistent FDG-avidity in residual masses, assessed 3-month postdefinitive RT, in pediatric RMS.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Materials and Methods:<\/jats:title>\n                    <jats:p>\n                      Children 15 years old or below with Group III\/IV RMS who received only definitive radiotherapy for local control from June 2013 to December 2018, and had\n                      <jats:sup>18<\/jats:sup>\n                      F-FDG-PET CT at 3 months post-RT were retrospectively analyzed for outcomes and other prognostic factors.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      Sixty-three children were eligible (Group III-55, Group IV-8).\n                      <jats:sup>18<\/jats:sup>\n                      F-FDG-PET CT scan done 3 months postradiotherapy showed FDG-avid residual masses in 10 patients (15.9%), anatomic residual in 24 (38.1%), and no anatomic\/FDG-avid residual in 29(46.0%). At a median follow-up of 38 months (interquartile range, 24 to 55\u00a0mo), 3-year EFS of patients with FDG-avid residual masses was 40.0% (95% CI: 18.7% to 85.5%) versus the rest of the cohort, which was 71.9% (95% CI: 59.8% to 86.5%) (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      =0.008). Three-year OS of patients with FDG-avid residual masses was 50.8% (95% CI: 25.7% to 100.0%) versus the rest of the cohort, which was 77.0% (95% CI: 65.1% to 91.0%) (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      =0.037). Presence of FDG-avid residual disease persisting post-RT affected both EFS [HR-3.34 (95% CI: 1.29 to 8.68) (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      =0.013)] and OS [HR-3.20 (95% CI: 1.01 to 10.12) (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      =0.048)] on univariate analysis and this significance was retained for EFS in multivariate analysis [HR-3.52 (95% CI: 1.33 to 9.30) (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      =0.011)].\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>Persistent metabolic activity in residual disease post-chemoradiotherapy in RMS may portend a poorer prognosis with an increased risk of relapse. This subset of high-risk patients needs to be identified, and further trials are warranted to develop strategies to improve their outcomes.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/mph.0000000000002565","type":"journal-article","created":{"date-parts":[[2022,10,17]],"date-time":"2022-10-17T15:01:26Z","timestamp":1666018886000},"page":"e363-e369","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":5,"title":["Can 18F-FDG-Positron Emission Tomography be a Prognostic Tool in Children With Rhabdomyosarcoma Treated With Definitive Radiotherapy?"],"prefix":"10.1097","volume":"45","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6459-2058","authenticated-orcid":false,"given":"Badira","family":"Cheriyalinkal Parambil","sequence":"first","affiliation":[{"name":"Pediatric Oncology"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sneha","family":"Shah","sequence":"additional","affiliation":[{"name":"Nuclear Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maya","family":"Prasad","sequence":"additional","affiliation":[{"name":"Pediatric Oncology"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tushar","family":"Vora","sequence":"additional","affiliation":[{"name":"Pediatric Oncology"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siddhartha","family":"Laskar","sequence":"additional","affiliation":[{"name":"Radiation Oncology"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nehal","family":"Khanna","sequence":"additional","affiliation":[{"name":"Radiation Oncology"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sajid","family":"Qureshi","sequence":"additional","affiliation":[{"name":"Surgical Oncology"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mukta","family":"Ramadwar","sequence":"additional","affiliation":[{"name":"Pathology"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seema","family":"Kembhavi","sequence":"additional","affiliation":[{"name":"Radiodiagnosis, Tata Memorial Hospital, Homi Bhabha National Institute, Mumbai, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hari","family":"Sankaran","sequence":"additional","affiliation":[{"name":"Pediatric Oncology"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Venkatesh","family":"Rangarajan","sequence":"additional","affiliation":[{"name":"Nuclear Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sonali","family":"Thakur","sequence":"additional","affiliation":[{"name":"Nuclear Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Girish","family":"Chinnaswamy","sequence":"additional","affiliation":[{"name":"Pediatric Oncology"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2022,10,14]]},"reference":[{"key":"R1-20250804","doi-asserted-by":"crossref","first-page":"3391","DOI":"10.1200\/JCO.2008.19.7483","article-title":"Comparing adult and pediatric rhabdomyosarcoma in the surveillance, epidemiology and end results program, 1973 to 2005: an analysis of 2,600 patients","volume":"27","author":"Sultan","year":"2009","journal-title":"J Clin Oncol"},{"key":"R2-20250804","doi-asserted-by":"crossref","first-page":"1411","DOI":"10.1002\/pbc.24532","article-title":"PAX-FOXO1 fusion status drives unfavorable outcome for children with rhabdomyosarcoma: a children\u2019s oncology group report","volume":"60","author":"Skapek","year":"2013","journal-title":"Pediatr Blood Cancer"},{"key":"R3-20250804","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1016\/j.ijrobp.2015.08.040","article-title":"Local control for intermediate-risk rhabdomyosarcoma: Results from D9803 according to histology, group, site, and size: A report from the children\u2019s oncology group","volume":"93","author":"Wolden","year":"2015","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"R4-20250804","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1097\/00043426-200003000-00005","article-title":"Presence of well-differentiated rhabdomyoblasts at the end of therapy for pelvic rhabdomyosarcoma: implications for the outcome","volume":"22","author":"Ortega","year":"2000","journal-title":"J Pediatr Hematol Oncol"},{"key":"R5-20250804","doi-asserted-by":"crossref","first-page":"3705","DOI":"10.1200\/JCO.2008.19.5933","article-title":"Prognostic significance of tumor response at the end of therapy in group III rhabdomyosarcoma: a report from the children\u2019s oncology group","volume":"27","author":"Rodeberg","year":"2009","journal-title":"J Clin Oncol"},{"key":"R6-20250804","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1097\/01.mph.0000212978.21372.97","article-title":"Significance of persistent mature rhabdomyoblasts in bladder\/prostate rhabdomyosarcoma: Results from IRS IV","volume":"28","author":"Arndt","year":"2006","journal-title":"J Pediatr Hematol Oncol"},{"key":"R7-20250804","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1182\/blood-2005-06-2252","article-title":"FDG-PET after two cycles of chemotherapy predicts treatment failure and progression-free survival in Hodgkin lymphoma","volume":"107","author":"Hutchings","year":"2006","journal-title":"Blood"},{"key":"R8-20250804","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1016\/j.ijrobp.2012.01.077","article-title":"Positron emission tomography (PET) evaluation after initial chemotherapy and radiation therapy predicts local control in rhabdomyosarcoma","volume":"84","author":"Dharmarajan","year":"2012","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"R9-20250804","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1016\/j.ijrobp.2014.08.005","article-title":"Predicting outcome in patients with rhabdomyosarcoma: role of [(18)f]fluorodeoxyglucose positron emission tomography","volume":"90","author":"Casey","year":"2014","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"R10-20250804","doi-asserted-by":"crossref","first-page":"3091","DOI":"10.1200\/JCO.2001.19.12.3091","article-title":"Intergroup rhabdomyosarcoma Study-IV: results for patients with nonmetastatic disease","volume":"19","author":"Crist","year":"2001","journal-title":"JCO"},{"key":"R11-20250804","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1200\/JCO.2003.06.129","article-title":"Prognostic factors and clinical outcomes in children and adolescents with metastatic rhabdomyosarcoma--a report from the Intergroup Rhabdomyosarcoma Study IV","volume":"21","author":"Breneman","year":"2003","journal-title":"J Clin Oncol"},{"key":"R12-20250804","doi-asserted-by":"crossref","first-page":"5182","DOI":"10.1200\/JCO.2009.22.3768","article-title":"Vincristine, actinomycin, and cyclophosphamide compared with vincristine, actinomycin, and cyclophosphamide alternating with vincristine, topotecan, and cyclophosphamide for intermediate-risk rhabdomyosarcoma: children\u2019s oncology group study D9803","volume":"27","author":"Arndt","year":"2009","journal-title":"J Clin Oncol"},{"key":"R13-20250804","doi-asserted-by":"crossref","first-page":"e26809","DOI":"10.1002\/pbc.26809","article-title":"Consensus and controversies regarding the treatment of rhabdomyosarcoma","volume":"65","author":"Borinstein","year":"2018","journal-title":"Pediatr Blood Cancer"},{"key":"R14-20250804","doi-asserted-by":"crossref","first-page":"1566","DOI":"10.1016\/S1470-2045(19)30617-5","article-title":"Vinorelbine and continuous low-dose cyclophosphamide as maintenance chemotherapy in patients with high-risk rhabdomyosarcoma (RMS 2005): a multicentre, open-label, randomised, phase 3 trial","volume":"20","author":"Bisogno","year":"2019","journal-title":"Lancet Oncol"},{"key":"R15-20250804","doi-asserted-by":"crossref","first-page":"1322","DOI":"10.1200\/JCO.2009.25.0803","article-title":"Comparison of the prognostic value of assessing tumor diameter versus tumor volume at diagnosis or in response to initial chemotherapy in rhabdomyosarcoma","volume":"28","author":"Ferrari","year":"2010","journal-title":"J Clin Oncol"}],"container-title":["Journal of Pediatric Hematology\/Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MPH.0000000000002565","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,4]],"date-time":"2025-08-04T20:07:40Z","timestamp":1754338060000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MPH.0000000000002565"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10,14]]},"references-count":15,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2023]]}},"URL":"https:\/\/doi.org\/10.1097\/mph.0000000000002565","relation":{},"ISSN":["1077-4114"],"issn-type":[{"value":"1077-4114","type":"print"}],"subject":[],"published":{"date-parts":[[2022,10,14]]},"assertion":[{"value":"2022-03-27","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-07-31","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}